While the US Food and Drug Administration approval of cetuximab for treating patients with head and neck carcinomas may have introduced another agent to oncologists, these agents
(that target oncogenes) have not yielded a prolonged clinical benefit for patients with head and neck cancer. In this activity, we will review recent clinical advancements in treating and managing patients with
recurrent and metastatic head and neck squamous cell carcinoma with a particular focus on recently approved immunotherapeutic agents called immune checkpoint inhibitors. Appropriate care of a patient
with human papilloma virus-associated oropharyngeal carcinoma will be delineated to illustrate some of the specific clinical issues that arise in managing patients with this type of cancer. The importance of
p16 testing of oropharyngeal carcinoma, the concept of deintensification in this patient population, and the new list of oncologic agents available for patients with recurrent or metastatic cancers will be
discussed. Lastly, the importance of multidisciplinary care in the management of these complex head and neck cancer patients will be highlighted.
The goal of this activity is to provide oncology healthcare providers with current and relevant clinical information on the management of patients with advanced head and neck
This activity is intended for healthcare providers on the interdisciplinary oncology team (including medical oncologists, oncology nurses, nurse practitioners, and oncology physician assistants) who are involved in the care and treatment of patients with head and neck cancers. No prerequisites required.
After participating in this activity, the participant will demonstrate the ability to:
- SUMMARIZE the workup of patients with head and neck squamous cell carcinoma (HNSCC).
- DESCRIBE the use of molecular and histologic tumor testing and prior treatment history in selecting a treatment strategy.
- EVALUATE the clinical utility of immune checkpoint inhibitors for the treatment of recurrent or metastatic HNSCC.
The Johns Hopkins University School takes responsibility for the content, quality, and scientific integrity of this CME activity.
Policy on Speaker and Provider Disclosure
It is the policy of the Johns Hopkins University School of Medicine that the speaker and provider globally disclose conflicts of interest. The Johns Hopkins University School of Medicine OCME has established
policies that will identify and resolve conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to presentation of the education.
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), Johns Hopkins University School of Medicine Office of Continuing Medical Education
(OCME) requires attested and signed global disclosure of the existence of all financial interests or relationships with commercial interest from any individual in a position to control the content of a CME
activity sponsored by OCME. The following relationships have been reported for this activity:
Dr. Ettinger reports serving as a principal investigator for Golden Biotechnology Corp; serving as a consultant for AbbVie Inc, BeyondSpring Pharmaceuticals, Inc, Boehringer-Ingelheim GmbH, Bristol-
Myers Squibb Company, Eli Lilly and Company, EMD Serono Inc, Guardant Health Inc, Genentech Inc, Helsinn Therapeutics Inc, Herron Therapeutics, and Sanofi-aventis, US LLC.
No other planners or faculty have indicated that they have any financial interests or relationships with a commercial entity.
Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grants, typically through the Office of Research Administration.
Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project
The following relationships have been reported for this activity:
Johns Hopkins University School of Medicine Chair and Planner
David S. Ettinger, MD
Alex Grass Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Young Jun Kim, MD, PhD
Amy and Barry Baker Endowed Chair
Co-Leader of Translational Research and Interventional Oncology
Vanderbilt Ingram Cancer Center
Director of Head and Neck Oncology Research
Department of Otolaryngology-Head and Neck Surgery
Vanderbilt University Medical Center
Bradley Reames, MD, MS
Department of Surgery
Johns Hopkins Hospital
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only.
Use of Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of
drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.
I certify that I am participating in this Johns Hopkins University School of Medicine activity for CME-accredited training and/or educational purposes.
I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations
(the “Privacy Regulations”). Protected health information is information about a person's health or treatment that identifies the person.
I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential. I agree not to post or
discuss this protected health information, including pictures and/or videos, on any social media site (eg, Facebook, Twitter, etc.), in any electronic messaging program or through any portable electronic
I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns
Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.
“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as sponsor of this activity, has relayed information with the CME attendees/participants and certify
that the visitor is here for training, education and/or observation purposes only.”
For CME questions, please contact the CME Office at 410-955-2959 or e-mail firstname.lastname@example.org.
Johns Hopkins University School of Medicine
Office of Continuing Medical Education
720 Rutland Avenue/ Turner 20
Baltimore, Maryland 21205-2195
Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/03)
(Updated 4/09 and 3/14)
Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of
RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.
The following is an interactive case module designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3
sections: an unaccredited pre-test, an interactive case study, and a CME post-test and evaluation. All 3 sections must be completed to receive CME credit. A certificate of participation will be available online
immediately following successful completion of the activity.